Igci Yusuf Ziya, Ozkaya Mesut, Korkmaz Hakan, Bozgeyik Esra, Bayraktar Recep, Ulasli Mustafa, Erkilic Suna, Eraydin Ayten, Oztuzcu Serdar
1 Department of Medical Biology, Faculty of Medicine, University of Gaziantep , Gaziantep, Turkey .
2 Department of Endocrinology, Faculty of Medicine, University of Gaziantep , Gaziantep, Turkey .
Genet Test Mol Biomarkers. 2015 Aug;19(8):418-23. doi: 10.1089/gtmb.2015.0062. Epub 2015 Jun 5.
Fine needle aspiration biopsy (FNAB) is a useful tool in the diagnosis of thyroid nodules. However, some limitations exist as approximately 25% of the cases cannot be distinguished with this method. Therefore, identification of novel diagnostic markers is very important in improving the papillary thyroid carcinoma (PTC) diagnosis. microRNAs (miRNAs) are small regulatory RNA molecules that have been involved in a variety of biological processes, including tumorigenesis. Moreover, determination of miRNAs with prognostic, diagnostic, and therapeutic potential is of a great interest today.
In the present study, we evaluated the expression level of miR-30a-5p in serum and FNAB samples of PTC patients.
A total of 60 cases were included in the study, with the patients subdivided into four groups; benign, atypical cells of undetermined significance (ACUS), malignant group, including Hurthle cell PTC (HC-PTC), and malignant without Hurthle cell PTC (non-HC-PTC). Peripheral blood and FNAB samples of the cases were collected. The serum and FNAB expression levels of miR-30a-5p among the groups were compared. The miR-30a-5p expression level was determined using real-time polymerase chain reaction (RT-PCR).
According to both pre- and postoperative pathological diagnosis, miR-30a-5p levels were significantly increased in both serum and FNAB samples of HC-PTC and non-HC-PTC groups compared to other groups. This increase was more evident in the non-HC-PTC group (p=0.0245 for FNAB, p=0.0166 for serum).
The results of this study suggest that miR-30a-5p might be a novel diagnostic marker candidate in PTC. Further studies are required to investigate this possibility.
细针穿刺活检（FNAB）是诊断甲状腺结节的一种有用工具。然而，该方法存在一些局限性，约25%的病例无法通过此方法鉴别。因此，鉴定新的诊断标志物对于改善甲状腺乳头状癌（PTC）的诊断非常重要。微小RNA（miRNA）是参与包括肿瘤发生在内的多种生物学过程的小调节RNA分子。此外，确定具有预后、诊断和治疗潜力的miRNA在当今备受关注。
在本研究中，我们评估了PTC患者血清和FNAB样本中miR-30a-5p的表达水平。
本研究共纳入60例患者，将其分为四组：良性组、意义未明的非典型细胞（ACUS）组、恶性组，包括许特莱细胞型PTC（HC-PTC）和无许特莱细胞型PTC（非HC-PTC）。收集病例的外周血和FNAB样本。比较各组中miR-30a-5p的血清和FNAB表达水平。使用实时聚合酶链反应（RT-PCR）测定miR-30a-5p的表达水平。
根据术前和术后病理诊断，与其他组相比，HC-PTC组和非HC-PTC组的血清和FNAB样本中miR-30a-5p水平均显著升高。这种升高在非HC-PTC组中更为明显（FNAB为p = 0.0245，血清为p = 0.0166）。
本研究结果表明，miR-30a-5p可能是PTC的一种新的诊断标志物候选物。需要进一步研究来探讨这种可能性。
